Next Step: Are you ready to see if you qualify for a personalized GLP-1 program
Garcia-Webb agrees and encourages people to speak with their providers about other medications they are taking before starting a GLP-1 medication and if they do not experience weight loss
Evidence and Research Comparison# Semaglutide Research# Semaglutide has one of the most extensive clinical evidence bases of any peptide therapeutic: SUSTAIN trials : Seven Phase 3 studies in type 2 diabetes demonstrating HbA1c reduction and weight loss STEP trials : Four Phase 3 studies in obesity
To use the Medicare GLP-1 Bridge benefit, patients generally need to meet all of the following: Be enrolled in Medicare Part D (a standalone prescription drug plan or Medicare Advantage plan with prescription drug coverage) Be at least 18 years old AND meet one of three BMI-based eligibility tiers (more restrictive than the general FDA label): Tier 1: BMI of 35 or higher (no additional conditions required), or Tier 2: BMI of 30 or higher WITH heart failure with preserved ejection fraction, OR uncontrolled hypertension (systolic blood pressure above 140 mm Hg or diastolic above 90 mm Hg despite treatment with two antihypertensive medications), OR chronic kidney disease stage 3a or above, or Tier 3: BMI of 27 or higher WITH prediabetes (per American Diabetes Association guidelines), previous myocardial infarction, previous stroke, or symptomatic peripheral artery disease Be using the medication in combination with current and ongoing lifestyle modification including structured nutrition and physical activity Have a prescription from a qualified prescriber (any licensed clinician with prescribing authority can prescribe
GHRP-6 is available for purchase as a research chemical in many jurisdictions
